Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is indeed one possibility that they are going to focus on the SPAC merger, but I would think that type of information is better distributed via SEC filings and press releases.
Since the NBC piece that mentioned IV trial results expected to be out this week (per the company), it wouldn't be a surprise that tomorrow morning top line results from the Phase III trial will be discussed.
While it might be good for the shareholders of BRPA if the merger were concluded before the results come out, there won't be enough time for the NeuroRX/BRPA merger to be finalized prior to results of the Phase III trial. In the SEC filings of BRPA, the S-4 still has blanks for dates of the vote on the merger etc.
Edit: Also, if this update were about the merger, certainly BRPA would be on the call as well. This call was billed as about NeuroRx business.
Right, so somebody's holdings of CYDY might have become available after they borrowed on margin from a margin account in which the CYDY shares are held. But aren't all margin accounts ripe for brokers borrowing against even if there is no current borrowing, by virtue of the fact that they are margin eligible and not cash (non-margin) accounts?
Not too familiar with that term or how it relates to the subject at hand. I have been here for far less than three years, which is ancient history in biotech, no? Regardless, it seems irrelevant to the discussion about a hack "journalist" and wannabe muckraker getting the facts wrong YET AGAIN. How many times can a hack be wrong about the subject of their articles before they have to look for another job?
Looks like some more covering from shorts today, based on the iBorrow view of available Interactive Brokers inventory:
https://iborrowdesk.com/report/CYDY
Now 2 million shares available, up from 1.5 million just this morning. 500,000 shares covered today?
If the matter was settled, would that be defined as illegal? Wouldn't it be up to a judge to decide questions of legality? I guess one could call it a lawsuit that was settled?
SETTLING
Who was the first to erroneously announce that Dr. Kelly's wife, Dr. Kelly, sold stock in CYDY, using the 144 filing as evidence? Did they issue a retraction like AF did?
CHORTLING
Could a NASDAQ uplisting announcement be coming soon? Perhaps today after market close? Something along the lines of CytoDyn going to NASDAQ Monday morning, February 8? I base this on the warrant exercises a week ago allowing CYDY to meet the final requirement of enough Stockholders' Equity. I also think some of the aftermarket press releases recently has been to demonstrate to NASDAQ that they are not trying to pump the stock.
Would be a great one-two punch to have us on the NASDAQ before the CD12 Phase III results are out.
Just stopped by to say congratulations to all you old Anavex friends who have stuck it out! I'm very happy for you all. Oh, the battles we had against the entire cesspool of short-biased hedge funds and crooked "journalists". The tide finally turned! While I haven't been in the stock for a while, I'm still celebrating your victory and wish for more to come!
Millstone
Can we be critical about his choice in electrical outlets?
Nice find! And tons and tons of new job openings being announced daily there, both in Switzerland and California.
https://careers.bachem.com/search?locale=en_US
I might go in for an interview...let's see, how do I demonstrate that I can science?
You mean 75% of existing biotechs currently listed on NASDAQ lol...
I think the results are going straight to the FDA as soon as humanly possible. They will be concurrently analyzed by CYDY and a topline report will be prepared for public consumption. I DO NOT believe they will wait to get the data to the FDA. On the contrary.
NASDAQ uplisting announcement - when can we expect it?
I am of the opinion that the uplisting comes first, say about Monday February 8. Perhaps it is announced later this week. Then the CD12 results are announced soon after.
We should meet ALL of the NASDAQ uplisting requirements right now, after the recent warrant exercises which filled the stockholders' equity tank.
It might be nice to be on the NASDAQ pre-CD12 results to give more people the opportunity to own shares, and perhaps to avail ourselves of options.
Gosh, that is a great question. If only you knew...if only you knew.
That's amazing news Marksch1! My best wishes for continued progress and healing.
I agree completely 4running. Don't believe anybody who claims the data will be released to the public on Monday, February 1. It could be released Monday, or it could be in a week. People who state that it WILL be released on Monday should not be believed. In fact, I think they are trying (in vain) to game the system.
Regardless, our time is almost here at last. RLFTF is going to bring some amazing data to the world soon.
Do you think the $CYDY share price increase is causing Jacob's Ma to Waver?
I personally don't mind waiting 2-3 weeks for the topline results of the Phase III trial. In the meantime, while we're all waiting, $CYDY can uplist to NASDAQ because they now fulfill all the uplisting requirements. Fun times!
In the video (
To short CYDY right now, one has to have the faith of a Jacobin. Because there is a confidence coming from various doctors and scientists who have used Leronlimab in an acute setting that, if I were short, would have me calling for my Ma-. Granted, Nader is a complicated fellow, given to exaggeration, yet sometimes even a story Weaver like him comes up with a storyline that has a good ending for shareholders.
Remember, it's about Leronlimab, not Nader. Don't lose sight of that. How will you feel if you are short this company, and they actually have a drug that helps in the worst cases of Covid-19? The one shorts have been bashing endlessly partly because the CEO was accused of selling fake Indian dreamcatchers 30 years ago?
"I have become the very thing I swore to destroy!" - Some Star Wars movie or something.
From SEC filings (Def 14A if you want to look it up):
"The Board has determined that each current member of the Audit Committee is financially sophisticated under the current listing standards of the Nasdaq. The Board has also determined that Mr. Timmins is an “audit committee financial expert” as defined in Regulation S-K Item 407(d)(5)(ii) adopted by the SEC. All current members of the Audit Committee are considered independent because they satisfy the independence requirements for board members prescribed by the NASDAQ Rules, including those set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended."
"We are not a “listed issuer” as that term is used in Regulation S-K Item 407 adopted by the Securities and Exchange Commission (the “SEC”). However, in determining director independence, we use the definition of independence in Rule 5605(a)(2) and rule 5605(c)(2) of the listing standards of The Nasdaq Stock Market (the “NASDAQ Rules”).
The Board has determined that Messrs. Naydenov, Timmins and Patel, and former director Dr. Welch are independent under the NASDAQ Rules in that each is not, and has not been, an executive officer or employee and does not otherwise have a relationship which, in the opinion of the Board, would interfere with his exercise of independent judgment in carrying out the responsibilities of a director."
Let's see, Audit Committee, check. Majority of independent board members. Is 3 out of 5 a majority? It seems so! Check.
NASDAQ bound, thanks for helping confirm.
According to the CFO of $CYDY, the last step in qualifying for NASDAQ under the standard they are aiming for is a couple million dollars cash that goes to stockholders' equity. I'm familiar with stockholders' equity and other terms that can be looked up on remedial investing websites.
Maybe it's more fun to list on NASDAQ first so more people will have the ability to buy the stock once data is released? It will bring many more eyes to the stock to be listed on NASDAQ before a data release.
Not that you truly want for an explanation, but here goes:
A couple Million $ in stockholders equity was needed on the books to qualify for one of the NASDAQ uplist tiers. It was the LAST item required for qualification.
They just raised a couple million or so. Interesting.
I did a cross-check of all the filings by DSGT with SEDAR after the CTO. DSGT has supplied every requested document. Now, we must wait until the regulator in British Columbia reviews and confirms for the CTO to be lifted. I'd think this would usually be fairly rapid, meaning a few days. DSGT submitted the last of the documents yesterday afternoon.
Canadian folks, can you confirm that buying of stock is only suspended in B.C.?
More filings coming in on the SEDAR site, including Exclusive Jonway distribution deal and Exclusive Skywell distribution MOU. It's there in black and white, filed with the System for Electronic Document Analysis and Retrieval (SEDAR) the Canadian stock market filing database.
I think there are a few more press releases for DSGT to upload, and they will be up to date. I don't know how long it will take for the Canadian regulators to lift the Cease Trade Order in Canada.
Link to SEDAR: https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00037215
Well said. I'll try now:
BY POSTING IN ALL CAPS CONSTANTLY, SOMEBODY MIGHT FINALLY LISTEN TO MY DOOM AND GLOOM SCENARIOS ABOUT RLFTF.
I WANT TO BE HEARD, SO I RESORT TO ALL CAPS. INSTEAD OF BEING HEARD THOUGH, PEOPLE MIGHT JUST BLOCK ME AND NEVER REALLY CONSIDER MY MESSAGES BECAUSE THEY COME ACROSS AS RANTING AND RAVING.
Great news tiggerifficm4! Thanks for posting the link to the story of another Covid survivor that was given RLF-100.
From the son's telling, it looked very grim. "Docs repeatedly told us he was very unlikely to recover" but he's now out of the ICU and in rehab.
Some hope amidst trying times for the U.S. I'm also heartened by the new administration's commitment to therapeutics.
Anybody have the email addresses of Bob Silzer and Rick Curtis? I'm a large shareholder with something I'd like to share with them.
Thanks in advance.
I did the same, and the same language comes up for most all doctors. It is template language regarding malpractice awards.
Thanks. I have so many shares right now that I sometimes add more as a way to counteract my inclination to sell on a drop. Trying to trick my brain. It sometimes works!
Bought more at the open at about .275. If results come out at the end of January it amounts to a couple week delay from the most recent estimates. Today's drop seems like an overreaction for a short delay.
So, as expected from reading the latest clinical trials site update, the company enrolled 196 patients, and the top line results will be available at the end of January or beginning of February. Meanwhile, expanded access continues around the country at 24 locations. About a month more to await unblinded results. I wish the FDA had granted the EUA already, based on the extraordinary EAP results with Aviptadil/RLF-100. I'm very confident the drug will be approved. So more time, which many don't have. Let's hope as many as possible are able to be treated through the EAP.
Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Geneva, Switzerland and Radnor, Pa, USA, December 30, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI(TM) (previously RLF-100TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. Enrollment was increased from 165 patients in order to amass as large a safety database as possible. Top line data are expected in late January - early February 2021.
"With FDA's authorization and the extraordinary dedication of our twelve clinical trial sites, we were able to take a drug not formulated or administered to patients in IV form since 2005 and advance it to the clinic in ten weeks. We hope that the highly encouraging results seen in the most critically-ill COVID-19 patients treated in our expanded access program can be replicated in patients who have Critical COVID-19 without an advanced comorbidity" said Prof. Jonathan Javitt, CEO and founder of NeuroRx, Inc. "The FDA did not agree to grant EUA, as applied for in September, based upon the open-label study reported earlier, but has advised us that they remain committed to working with us in the development of our product and will promptly review the forthcoming data from this randomized trial. Until that time, available stocks of ZYESAMITM (RLF-100TM) will continue to be administered under our Expanded Access Protocol and individual patient requests under Right to Try laws."
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We congratulate NeuroRx on the successful completion of patient enrollment in this crucial pivotal clinical study and look forward to the top line results. Our fervent hope is for RLF-100TM to bring benefit to critically ill patients suffering the consequences of COVID-19 infection."
It is getting halted continuously today for volatility reasons. A trade imbalance stops trading for I think 10 minutes each time. Here's a link: https://www.nasdaqtrader.com/trader.aspx?id=TradeHalts#
You are aware that NeuroRx, our partner, is merging into BRPA? So this is not the wrong board to discuss. Also, float is different than total shares outstanding.
BRPA has a float of only 600,000 shares, and the SPAC chasers have gotten a hold of it. That, combined with the amazing results so far with Aviptadil / RLF-100 have people charging into BRPA. EVENTUALLY, it will equalize with our RLFTF. But remember that the share count is vastly different, BRPA is now a Nasdaq listed vehicle, and easy for the robinhooders to trade. I'm frustrated that Relief is not seeing the benefits as well, but it will in time.
The fund that owns a majority of RLFTF, Global Emerging Markets (GEM) has every interest in Relief's stock going up as much as possible! They also own stock in NeuroRx (I don't know how much but I guess we can find out in the BRPA filings). Both RLFTF and BRPA will benefit. RLFTF stands to be worth more because of its 80/20 ownership in most of the world. BRPA is probably going up because the robinhood crowd has discovered it and it is easier for them to buy, being on the Nasdaq. The sharp ones will discover RLFTF also.
BRPA last price was $21.68 before a Nasdaq Halt. Per the below link, the halt is a pause related to volatility (code: LUDP).
The bid and ask are nuts right now though, at $30.00 / $26.50
So once the halt is lifted, we could see BRPA up another $9...
https://www.nasdaqtrader.com/trader.aspx?id=TradeHalts#
BRPA is the SPAC ticker that NeuroRx is merging into. NeuroRx is our partner that is heading the U.S. clinical trials etc. (for those not up to date)
Yeah, it's been a tough hold. Admittedly the majority of my therapeutics holdings are now in Relief, with a small amount in the other one that I dare not name on this board. But HGEN is one of the real contenders, with a solid scientific rationale and solid management. Glad to see the market recognizing its strengths.